UroEvidenceHub - Prostate Cancer Real-World Data Registry (ProReg)
Research type
Research Study
Full title
UroEvidenceHub (UEH) - Prostate Cancer Patients Real World Data Prospective Registry
IRAS ID
366975
Contact name
Muhammad Imran Omar
Contact email
Sponsor organisation
Stichting EAU UroEvidenceHub (UEH)
Duration of Study in the UK
9 years, 11 months, 29 days
Research summary
Prostate cancer is the most common cancer in men in Europe. Although many treatments and investigations are available, we still do not fully understand which approaches work best for different groups of patients in everyday clinical practice. Clinical trials are helpful, but they often involve only selected patients and may not show what happens in the real world, where people have different ages, health conditions, and treatment needs.
This study is part of the UroEvidenceHub Prostate Cancer Registry (ProReg), an international project led by the European Association of Urology. The aim is to collect better information about how men with prostate cancer are diagnosed, monitored, and treated across Europe, including here in the NHS. The study will gather information that is already routinely recorded during a patient’s normal care—such as PSA blood tests, scans, treatments, and follow-up results.
Patients who take part will also be asked to complete short questionnaires about their symptoms, general health, and experience of their care. These questionnaires are commonly used in routine urology practice and help us understand how prostate cancer and its treatments affect day-to-day life.
Taking part will not change a patient’s care in any way, and no extra hospital visits are required. All identifiable information will remain within NHS systems. Only pseudonymised data (with names and personal details removed) will be securely transferred to the central registry in the EU.
By bringing together information from many hospitals, the registry will help us learn which treatments achieve the best outcomes, how quality of life changes over time, and where care could be improved. The results will contribute to better clinical guidelines and future research. Patients can withdraw at any time without affecting their treatment.
REC name
East Midlands - Leicester South Research Ethics Committee
REC reference
26/EM/0020
Date of REC Opinion
14 Jan 2026
REC opinion
Favourable Opinion